Is BTTX or UPHL more profitable?

Company Net Margins Return on Equity Return on Assets Better Therapeutics N/A N/A N/A UpHealth N/A N/A N/A

Is UPHL or CLVR more profitable?

Company Net Margins Return on Equity Return on Assets UpHealth N/A N/A N/A Clever Leaves N/A N/A N/A

Does the media favor UPHL or CLVR?

In the previous week, UpHealth and UpHealth both had 1 articles in the media. Clever Leaves' average media sentiment score of 0.00 beat UpHealth's score of -0.71 indicating that Clever Leaves is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UpHealth 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Clever Leaves 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, VRAYQ or UPHL?

UpHealth has higher revenue and earnings than ViewRay. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ViewRay $102.21M 0.00 -$107.33M N/A N/A UpHealth $130M 0.00 -$56.42M $1.98 0.00

Is VRAYQ or UPHL more profitable?

Company Net Margins Return on Equity Return on Assets ViewRay N/A N/A N/A UpHealth N/A N/A N/A

Which has stronger valuation & earnings, UPHL or IMAC?

IMAC has lower revenue, but higher earnings than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio UpHealth $130M 0.00 -$56.42M $1.98 0.00 IMAC $15.22M 0.00 -$10.54M -$0.27 N/A

Is UPHL or IMAC more profitable?

UpHealth has a net margin of 0.00% compared to IMAC's net margin of -75.40%. UpHealth's return on equity of 0.00% beat IMAC's return on equity. Company Net Margins Return on Equity Return on Assets UpHealth N/A N/A N/A IMAC -75.40% -52.17% -34.51%

Does the media favor UPHL or IMAC?

In the previous week, IMAC had 1 more articles in the media than UpHealth. MarketBeat recorded 2 mentions for IMAC and 1 mentions for UpHealth. IMAC's average media sentiment score of 0.14 beat UpHealth's score of -0.71 indicating that IMAC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UpHealth 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative IMAC 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is UPHL or SYRS more profitable?

UpHealth's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets UpHealth N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

UpHealth (UPHL) Competitors

$0.0003 0.00 (0.00%)

As of 08/19/2026

Compare

UPHL vs. BTTX, CLVR, VRAYQ, IMAC, and SYRS

Should you buy UpHealth stock or one of its competitors? UpHealth's main competitors and comparable companies include Better Therapeutics (BTTX), Clever Leaves (CLVR), ViewRay (VRAYQ), IMAC (IMAC), and Syros Pharmaceuticals (SYRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does UpHealth compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and UpHealth (NYSE:UPHL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Better Therapeutics has higher earnings, but lower revenue than UpHealth. Better Therapeutics is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Better Therapeutics	N/A	N/A	-$39.76M	-$0.39	N/A
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00

In the previous week, UpHealth had 1 more articles in the media than Better Therapeutics. MarketBeat recorded 1 mentions for UpHealth and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat UpHealth's score of -0.71 indicating that Better Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Better Therapeutics	Neutral
UpHealth	Negative

Company	Net Margins	Return on Equity	Return on Assets
Better Therapeutics	N/A	N/A	N/A
UpHealth	N/A	N/A	N/A

Better Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, UpHealth has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 56.1% of UpHealth shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 34.2% of UpHealth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

UpHealth beats Better Therapeutics on 5 of the 9 factors compared between the two stocks.

How does UpHealth compare to Clever Leaves?

UpHealth (NYSE:UPHL) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Clever Leaves has lower revenue, but higher earnings than UpHealth. Clever Leaves is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

UpHealth has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, indicating that its share price is 381,513% more volatile than the broader market.

56.1% of UpHealth shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 34.2% of UpHealth shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, UpHealth and UpHealth both had 1 articles in the media. Clever Leaves' average media sentiment score of 0.00 beat UpHealth's score of -0.71 indicating that Clever Leaves is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
UpHealth	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Clever Leaves	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
UpHealth	N/A	N/A	N/A
Clever Leaves	N/A	N/A	N/A

Summary

UpHealth beats Clever Leaves on 5 of the 9 factors compared between the two stocks.

How does UpHealth compare to ViewRay?

ViewRay (NASDAQ:VRAYQ) and UpHealth (NYSE:UPHL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

15.5% of ViewRay shares are held by institutional investors. Comparatively, 56.1% of UpHealth shares are held by institutional investors. 2.5% of ViewRay shares are held by company insiders. Comparatively, 34.2% of UpHealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

UpHealth has higher revenue and earnings than ViewRay.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ViewRay	$102.21M	0.00	-$107.33M	N/A	N/A
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00

In the previous week, UpHealth had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for UpHealth and 0 mentions for ViewRay. ViewRay's average media sentiment score of 0.00 beat UpHealth's score of -0.71 indicating that ViewRay is being referred to more favorably in the media.

Company	Overall Sentiment
ViewRay	Neutral
UpHealth	Negative

ViewRay has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, UpHealth has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
ViewRay	N/A	N/A	N/A
UpHealth	N/A	N/A	N/A

Summary

UpHealth beats ViewRay on 6 of the 8 factors compared between the two stocks.

How does UpHealth compare to IMAC?

UpHealth (NYSE:UPHL) and IMAC (NASDAQ:IMAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, IMAC had 1 more articles in the media than UpHealth. MarketBeat recorded 2 mentions for IMAC and 1 mentions for UpHealth. IMAC's average media sentiment score of 0.14 beat UpHealth's score of -0.71 indicating that IMAC is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
UpHealth	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
IMAC	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.1% of UpHealth shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 34.2% of UpHealth shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IMAC has lower revenue, but higher earnings than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00
IMAC	$15.22M	0.00	-$10.54M	-$0.27	N/A

UpHealth has a net margin of 0.00% compared to IMAC's net margin of -75.40%. UpHealth's return on equity of 0.00% beat IMAC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
UpHealth	N/A	N/A	N/A
IMAC	-75.40%	-52.17%	-34.51%

UpHealth has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, IMAC has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market.

Summary

UpHealth beats IMAC on 9 of the 13 factors compared between the two stocks.

How does UpHealth compare to Syros Pharmaceuticals?

UpHealth (NYSE:UPHL) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, UpHealth had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 1 mentions for UpHealth and 0 mentions for Syros Pharmaceuticals. Syros Pharmaceuticals' average media sentiment score of 0.00 beat UpHealth's score of -0.71 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
UpHealth	Negative
Syros Pharmaceuticals	Neutral

UpHealth has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UpHealth	$130M	0.00	-$56.42M	$1.98	0.00
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

UpHealth has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

UpHealth's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
UpHealth	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

56.1% of UpHealth shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 34.2% of UpHealth shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

UpHealth beats Syros Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get UpHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPHL vs. The Competition

Export

Metric	UpHealth	Health services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6K	$837.00K	$7.37B	$24.27B
Dividend Yield	N/A	N/A	2.53%	3.70%
P/E Ratio	0.00	N/A	268.43	29.99
Price / Sales	0.00	0.00	621.40	20.82
Price / Cash	N/A	N/A	78.13	32.31
Price / Book	0.00	0.00	13.07	6.75
Net Income	-$56.42M	-$48.09M	$3.46B	$1.07B
7 Day Performance	N/A	N/A	1.43%	-1.25%
1 Month Performance	N/A	N/A	4.58%	2.27%
1 Year Performance	N/A	N/A	27.60%	17.37%

UpHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
UPHL UpHealth	N/A	$0.00 flat	N/A	+50.0%	$6K	$130M	N/A	1,750
BTTX Better Therapeutics	N/A	$0.00 flat	N/A	N/A	$4K	N/A	N/A	40
CLVR Clever Leaves	N/A	N/A	N/A	N/A	$18K	$17.42M	N/A	560
VRAYQ ViewRay	N/A	N/A	N/A	N/A	$16K	$102.21M	N/A	300
IMAC IMAC	N/A	$0.00 flat	N/A	N/A	$13K	$15.22M	N/A	106

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:UPHL) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

UpHealth (UPHL) Competitors

UPHL vs. BTTX, CLVR, VRAYQ, IMAC, and SYRS

How does UpHealth compare to Better Therapeutics?

Summary

How does UpHealth compare to Clever Leaves?

Summary

How does UpHealth compare to ViewRay?

Summary

How does UpHealth compare to IMAC?

Summary

How does UpHealth compare to Syros Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPHL vs. The Competition

UpHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

UpHealth (UPHL) Competitors

UPHL vs. BTTX, CLVR, VRAYQ, IMAC, and SYRS

How does UpHealth compare to Better Therapeutics?

Which has preferable earnings and valuation, BTTX or UPHL?

Does the media prefer BTTX or UPHL?

Is BTTX or UPHL more profitable?

Which has more volatility & risk, BTTX or UPHL?

Do insiders & institutionals hold more shares of BTTX or UPHL?

Summary

How does UpHealth compare to Clever Leaves?

Which has higher valuation & earnings, UPHL or CLVR?

Which has more volatility & risk, UPHL or CLVR?

Do institutionals and insiders believe in UPHL or CLVR?

Does the media favor UPHL or CLVR?

Is UPHL or CLVR more profitable?

Summary

How does UpHealth compare to ViewRay?

Do institutionals & insiders hold more shares of VRAYQ or UPHL?

Which has higher earnings & valuation, VRAYQ or UPHL?

Does the media refer more to VRAYQ or UPHL?

Which has more volatility and risk, VRAYQ or UPHL?

Is VRAYQ or UPHL more profitable?

Summary

How does UpHealth compare to IMAC?

Does the media favor UPHL or IMAC?

Do institutionals & insiders hold more shares of UPHL or IMAC?

Which has stronger valuation & earnings, UPHL or IMAC?

Is UPHL or IMAC more profitable?

Which has more risk & volatility, UPHL or IMAC?

Summary

How does UpHealth compare to Syros Pharmaceuticals?

Does the media prefer UPHL or SYRS?

Which has better earnings and valuation, UPHL or SYRS?

Which has more risk & volatility, UPHL or SYRS?

Is UPHL or SYRS more profitable?

Do insiders & institutionals have more ownership in UPHL or SYRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPHL vs. The Competition

UpHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools